Physician profile
Kathryn Mooney
NPI 1881420560
$6,438.60
in general payments reported to CMS, 2019-2025
15 companies · $2,380 in 2025
The $2,380 reported for 2025 was more than what 82% of Oncology (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $263).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $231 · 2023: $455 · 2024: $3,372 · 2025: $2,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,813 · Food and Beverage: $1,888 · Travel and Lodging: $497 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $454 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,812.50 |
| Food and Beverage | $1,888.47 |
| Travel and Lodging | $497.40 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $453.74 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,274.71 | 2024-2025 | Carvykti, Rybrevant, Tecvayli |
| Astrazeneca Pharmaceuticals Lp | $647.13 | 2024-2025 | |
| Genmab U.S., INC. | $408.98 | 2024-2025 | Epkinly |
| Taiho Oncology, INC. | $356.76 | 2024 | |
| Daiichi Sankyo INC. | $299.91 | 2025 | Datroway, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $218.48 | 2024-2025 | Opdivo, Reblozyl |
| Amgen INC. | $135.62 | 2024 | |
| Celgene Corporation | $115.49 | 2024-2025 | Reblozyl |
| Regeneron Healthcare Solutions, INC. | $94.21 | 2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $59.79 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $47.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $32.22 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $23.39 | 2024 | Onivyde |
| Genentech USA, INC. | $22.57 | 2024 | |
| Legend Biotech USA INC. | $15.84 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Mooney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.